ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
David C. Newman
Peter W. Grant
Hugh D. Wolfenden
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dignan, R. J.
Right arrow Articles by Wolfenden, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dignan, R. J.
Right arrow Articles by Wolfenden, H. D.
Related Collections
Right arrow Coronary disease
Right arrow Extracorporeal circulation

Ann Thorac Surg 2001;71:158-164
© 2001 The Society of Thoracic Surgeons

Original article: cardiovascular

Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations

Rebecca J. Dignan, MDa, David W. Law, BSca, Peng W. Seah, MBBSa, Con W. Manganas, MBBSa, David C. Newman, FRACSa, Peter W. Grant, FRACSa, Hugh D. Wolfenden, FRACSa

a Prince of Wales Hospital, Sydney, Australia

Address reprint requests to Dr Dignan, Department of Cardiothoracic Surgery, 2986 The Vanderbilt Clinic, Nashville, TN37232
e-mail: rebecca.dignan{at}surgery.mc.vanderbilt.edu

Presented at the Thirty-sixth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 31–Feb 2, 2000.

Background. The recommended dose of aprotinin has been shown to reduce blood loss and need for blood transfusions, but the cost precludes its routine use. This study was designed to determine whether a less expensive, ultra-low dose of aprotinin is effective when used in coronary artery bypass grafting with left internal mammary artery.

Methods. Patients (n = 202) were randomized to receive either placebo or aprotinin, 0.5 million KIU before incision and 0.5 million KIU during initiation of cardiopulmonary bypass. Differences in quantity of blood transfused were analyzed. Further groups were analyzed to account for the effect of aspirin. Multivariable analysis was performed to determine risk factors for transfusion. Direct costs of blood products and aprotinin were tabulated for each group.

Results. There was an important reduction in the proportion of patients transfused, and number of blood units transfused when aprotinin was given before coronary artery bypass grafting. These differences were even more important in patients on aspirin preoperatively. Independent predictors for increased number of transfusions were aspirin continued before operation, smaller body surface area, and the use of placebo instead of ultra-low dose aprotinin. There was no difference in morbidity between treatment groups. There was a reduction in direct costs associated with the use of aprotinin.

Conclusions. These data support the routine use of aprotinin 1 million KIU in coronary artery bypass grafting with left internal mammary artery to reduce cost and transfusion requirements.




This article has been cited by other articles:


Home page
 Br J AnaesthHome page
D. R. McIlroy, P. S. Myles, L. E. Phillips, and J. A. Smith
Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis
Br. J. Anaesth., February 1, 2009; 102(2): 168 - 178.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al.
Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline
Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
A. Ronald and J. Dunning
Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery?
Interactive CardioVascular and Thoracic Surgery, December 1, 2006; 5(6): 767 - 773.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Sedrakyan, A. Wu, G. Sedrakyan, M. Diener-West, M. Tranquilli, and J. Elefteriades
Aprotinin use in thoracic aortic surgery: Safety and outcomes
J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 909 - 917.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro
Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?
Clinical Trials, June 1, 2005; 2(3): 218 - 232.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Kaminishi, Y. Hiramatsu, Y. Watanabe, Y. Yoshimura, and Y. Sakakibara
Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass
Ann. Thorac. Surg., February 1, 2004; 77(2): 644 - 650.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
D. Zabeeda, B. Medalion, M. Sverdlov, S. Ezra, A. Schachner, T. Ezri, and A. J. Cohen
Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization
Ann. Thorac. Surg., September 1, 2002; 74(3): 733 - 738.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The Society of Thoracic Surgeons.